Global Acellular Dermal Matrices Market – Drivers
Global Acellular Dermal Matrices Market: Restraint
Regulatory challenges: Stringent regulatory approval processes for medical devices including acellular dermal matrices is expected to hinder the global acellular dermal matrices market growth. For instance, in March 2021, The U.S. Food and Drug Administration (FDA) released a safety communication external site pertaining to Acellular Dermal Matrices (ADM) products used in implant-based breast reconstruction. According to the U.S. FDA's review, two ADMs named FlexHD developed by MTF Biologics, a global non-profit organization and Allomax developed by BD, a medical device company may have a greater risk profile than others. Two years after surgery, there were greater incidence of serious problems, explanation, further procedures, and infections.
To counterbalance the restraint, key players should focus on increasing the safety and efficacy of ADM products.
Regulatory challenges
Acellular Dermal Matrices Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients